Functional RET G691S polymorphism in cutaneous malignant melanoma

Oncogene

Volumn 28, Issue 34, 2009, Pages 3058-3068

  Narita, N ^a   Tanemura, A ^a   Murali, R ^b   Scolyer, R A ^b   Huang, S ^a   Arigami, T ^a   Yanagita, S ^a   Chong, K K ^a   Thompson, J F ^b   Morton, D L ^a   Hoon, D S ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

BRAF; Desmoplastic; Melanoma; Mutation; Polymorphism; RET

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN RET;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MELANOMA; MUTATION; PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; WILD TYPE;

ACTINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM INVASIVENESS; PHOSPHORYLATION; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RET; SKIN NEOPLASMS;

EID: 69449087581     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.164     Document Type: Article

References (42)

1. Airaksinen MS, Saarma M. (2002). The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383-394.
2. Bounacer A, Du Villard JA, Wicker R, Caillou B, Schlumberger M, Sarasin A et al. (2002). Association of RET codon 691 polymorphism in radiation-induced human thyroid tumours with C-cell hyperplasia in peritumoural tissue. Br J Cancer 86: 1929-1936. (Pubitemid 34888631)
3. Busam KJ. (2005). Cutaneous desmoplastic melanoma. Adv Anat Pathol 12: 92-102.
4. Busam KJ, Zhao H, Coit DG, Kucukgol D, Jungbluth AA, Nobrega J et al. (2005). Distinction of desmoplastic melanoma from nondesmoplastic melanoma by gene expression profiling. J Invest Dermatol 124: 412-418. (Pubitemid 40175890)
5. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM et al. (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98: 326-334. (Pubitemid 43338212)
6. Ceccherini I, Hofstra RM, Luo Y, Stulp RP, Barone V, Stelwagen T et al. (1994). DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 9: 3025-3029. (Pubitemid 24296781)
7. Curtin JA, Busam K, Pinkel D, Bastian BC. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340-4346. (Pubitemid 46630793)
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949-954. (Pubitemid 34716871)
9. Davison JM, Rosenbaum E, Barrett TL, Goldenberg D, Hoque MO, Sidransky D et al. (2005). Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 103: 788-792. (Pubitemid 40216408)
10. Dhomen N, Marais R. (2007). New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17: 31-39. (Pubitemid 46109299)
11. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R et al. (2004). RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 89: 3579-3584. (Pubitemid 38951937)
12. Fujiwara Y, Chi DD, Wang H, Keleman P, Morton DL, Turner R et al. (1999). Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res 59: 1567-1571. (Pubitemid 29160127)
13. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S et al. (2008). Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 7: 3642-3653.
14. Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K et al. (2006). A new melanoma antigen fatty acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res 66: 4443-4449.
15. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ et al. (2007). Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117: 719-729. (Pubitemid 46348530)
16. Gumireddy K, Sun F, Klein-Szanto AJ, Gibbins JM, Gimotty PA, Saunders AJ et al. (2007). in vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci USA 104: 6696-6701. (Pubitemid 47175563)
17. Hoon DS, Kuo CT, Wascher RA, Fournier P, Wang HJ, O'Day SJ. (2001). Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients. J Invest Dermatol 117: 375-378. (Pubitemid 34205726)
18. Iwamoto T, Taniguchi M, Asai N, Ohkusu K, Nakashima I, Takahashi M. (1993). cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene 8: 1087-1091. (Pubitemid 23087445)
19. Jaroszewski DE, Pockaj BA, DiCaudo DJ, Bite U. (2001). The clinical behavior of desmoplastic melanoma. Am J Surg 182: 590-595.
20. Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M et al. (2005). The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 96: 143-148. (Pubitemid 40575914)
21. Kondo T, Ezzat S, Asa SL. (2006). Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292-306.
22. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT et al. (2005). Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 23: 8057-8064. (Pubitemid 46657408)
23. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132. (Pubitemid 23186789)
24. Livestro DP, Muzikansky A, Kaine EM, Flotte TJ, Sober AJ, Mihm Jr MC et al. (2005). Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol 23: 6739-6746. (Pubitemid 46190269)
25. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G et al. (2005). The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115: 1068-1081. (Pubitemid 40489412)
26. Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M et al. (2006). Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol 37: 199-212. (Pubitemid 44615293)
27. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP et al. (2007). Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282: 29230-29240. (Pubitemid 350043334)
28. Quinn MJ, Crotty KA, Thompson JF, Coates AS, O'Brien CJ, McCarthy WH. (1998). Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 83: 1128-1135. (Pubitemid 28419065)
29. Runeberg-Roos P, Saarma M. (2007). Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann Med 39: 572-580. (Pubitemid 350175309)
30. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL et al. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759. (Pubitemid 36231971)
31. Sawai H, Okada Y, Kazanjian K, Kim J, Hasan S, Hines OJ et al. (2005). The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 65: 11536-11544. (Pubitemid 41821712)
32. Selek U, Chang EL, Hassenbusch III SJ, Shiu AS, Lang FF, Allen P et al. (2004). Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59: 1097-1106. (Pubitemid 38834303)
33. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. (2004). Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10: 1753-1757. (Pubitemid 38435567)
34. Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J et al. (2007). Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 13: 2068-2074. (Pubitemid 46649874)
35. Stephens LA, Powell NG, Grubb J, Jeremiah SJ, Bethel JA, Demidchik EP et al. (2005). Investigation of loss of heterozygosity and SNP frequencies in the RET gene in papillary thyroid carcinoma. Thyroid 15: 100-104. (Pubitemid 40344355)
36. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K et al. (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23: 6031-6039. (Pubitemid 39178855)
37. Takahashi M. (2001). The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12: 361-373.
38. Takahashi M, Buma Y, Hiai H. (1989). Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene 4: 805-806. (Pubitemid 19150663)
39. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. (1988). Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3: 571-578. (Pubitemid 19003664)
40. Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE et al. (2005). Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 24: 4721-4727. (Pubitemid 41032608)
41. Weber F, Eng C. (2008). Update on the molecular diagnosis of endocrine tumors: toward -omics-based personalized healthcare? J Clin Endocrinol Metab 93: 1097-1104.
42. Zbuk KM, Eng C. (2007). Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 7: 35-45.